Status:

COMPLETED

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Lead Sponsor:

Amgen

Conditions:

Thyroid Associated Ophthalmopathies

Thyroid-Associated Ophthalmopathy

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The primary objective of this study is to investigate the efficacy, safety, and tolerability of RV 001 (teprotumumab), a fully human anti-IGF1R antibody, administered q3W for 6 months, in comparison t...

Detailed Description

Study with completed results acquired from Horizon in 2024.

Eligibility Criteria

Inclusion

  • Clinical diagnosis of Graves' disease associated with active TED and a clinical activity score of ≥ 4
  • Fewer than 9 months from onset of TED
  • No previous medical or surgical treatment, excluding local supportive measures and oral steroids if the maximum cumulative dose is less than 1000 mg methylprednisolone or equivalent with at least 6 weeks between last administration of oral steroids and randomization
  • Euthyroid or with mild hypo or hyperthyroidism defined as free thyroxine (FT4) and free triiodothyronine (FT3) levels less than 50% above or below the normal limits (every effort should be made to correct the mild hypo- or hyperthyroidism promptly)

Exclusion

  • Optic neuropathy
  • Corneal decompensation unresponsive to medical management
  • Oral or IV steroid treatment for any non-TED reason in the preceding 3 months
  • Poorly controlled diabetes
  • Platelets \< 100 x 10\^9/L
  • Hemoglobin concentration \> 2 g/dL below the lower limit of normal

Key Trial Info

Start Date :

July 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 22 2017

Estimated Enrollment :

88 Patients enrolled

Trial Details

Trial ID

NCT01868997

Start Date

July 1 2013

End Date

February 22 2017

Last Update

December 17 2024

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

Jules Stein Eye Institute at UCLA

Los Angeles, California, United States, 90095

2

University of Denver

Aurora, Colorado, United States, 80045

3

Emory University Department of Ophthalmology

Atlanta, Georgia, United States, 30322

4

University of Iowa Hospitals and Clinics, Department of Ophthalmology

Iowa City, Iowa, United States, 52242

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease | DecenTrialz